Fidson Selected to Expand Influenza Treatment Access, Pandemic Preparedness

Fidson Healthcare Plc has been chosen as one of eleven manufacturers from nine countries to enter into sublicence agreements with the Medicines Patent Pool (MPP) for producing generic versions of baloxavir marboxil, an innovative antiviral treatment for influenza. This agreement is part of the MPP's voluntary licensing arrangement with Roche.

Charles Gore, the Executive Director of the Medicines Patent Pool, noted that they are now entering the implementation phase with manufacturers across various regions. The primary goal is to expedite the availability of quality-assured generic baloxavir by working closely with these manufacturers to support product development and regulatory approval.

Roche's Vice President and Head of Global Policy, Tamara Schudel, emphasized that transitioning from the initial agreement to actual sublicensing manufacturers is a significant milestone. She highlighted the importance of organizations trusting each other and working pragmatically towards a shared goal. Fidson Healthcare's Managing Director and CEO, Biola Adebayo, expressed that being selected as a sublicensee under the Roche-MPP voluntary licensing program for baloxavir marboxil is both an honor and a testament to Fidson's dedication to quality-assured pharmaceutical manufacturing, innovation, and enhancing healthcare outcomes.